Interventional Not yet recruiting Early Phase 1
NCT04690608 on ClinicalTrials.gov
Suprachoroidal Injection of Triamcinolone Acetonide in Resistant Diabetic Macular Edema, CRVO, Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema Following Pars Plana Vitrectomy
Official title: Resistant Diabetic Macular Edema and Suprachoroidal Injection
- Sponsor: Tanta University
- Enrollment: 100 (Estimated)
- Study start: 2024-12-01 (Estimated)
- Primary completion: 2024-12-01 (Estimated)
- Study completion: 2025-02-01 (Estimated)
- Allocation: N/a
- InterventionModel: Single Group
- InterventionModelDescription: cases of resistant diabetic macular edema and central retinal vein occlusion
- Masking: None
- PrimaryPurpose: Treatment
Brief Summary
Prospective interventional study on 60 eyes of resistant diabetic macular edema and central retinal vein occlusion that will receive suprachoroidal injection of Triamcinolone Acetonide (SCTA).
Conditions
- Retinal Edema
Intervention / Treatment
- Drug: Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1
Primary Outcome Measures
-
Improvement of central macular thickness
(1 month)
Reduction of the central macular thickness below 300 um
Countries
Egypt
Locations and Investigators
- Tanta University, Tanta, Egypt
Study Officials
- Amin E Nawar, Lecturer (Principal Investigator) — Faculty of medicine, Tanta University